The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because they have dramatic efficacy. At the same time, safety concerns about biologics have been raised. In this paper, we focus on the safety profile of biologics for psoriasis. As of 2017, six biologics are available in Japan. Two tumor necrosis factor-a inhibitors; infliximab and adalimumab, one anti-interleukin (IL)-12/23p40 antibody; ustekinumab, and IL-17 inhibitors; secukinumab, ixekizumab and brodalumab. Secukinumab and ixekizumab are anti-IL-17A antibodies. Brodalumab is an anti-IL17RA antibody. In this review, we pick up topics which have drawn attention regarding the safety of biologics and discuss them with recent published work.
INTRODUCTION
Psoriasis is a chronic inflammatory skin disease which impairs patients' quality of life severely. It has been recognized not just as a skin disease but as a systemic disease because it also causes arthritis and mental disorder; furthermore, an association with cardiovascular events is indicated. 1 In the past, when only topical treatment, phototherapy and oral systemic therapy were available, some patients could obtain limited satisfaction due to their insufficient effectiveness and their adverse events. The advent of biologics brought about a paradigm shift in psoriasis treatment and understanding the pathogenesis of psoriasis. Whereas biologics have shown dramatically excellent efficacy, their safety has been of concern. In this paper, we focus on the safety profile of biologics in psoriatic patients. As of 2017, six biologics are available in Japan. Two tumor necrosis factor (TNF)-a inhibitors; infliximab and adalimumab, one anti-interleukin (IL)-12/23p40 antibody; ustekinumab, and IL-17 inhibitors; secukinumab, ixekizumab and brodalumab. Secukinumab and ixekizumab are anti-IL-17A antibodies. Brodalumab is an anti-IL17RA antibody. In this review, we pick up topics which have drawn attention about the safety of biologics and discuss them with recent published work.
SAFETY CONCERNS SPECIFIC FOR EACH BIOLOGIC TNF-a inhibitors: infliximab and adalimumab
Six trials showed superior efficacy of infliximab to placebo. [2] [3] [4] [5] [6] [7] The incidence of adverse events and serious adverse events were similar in each infliximab-treated group. Generally, infliximab was well tolerated for most patients. 8 In Japan, high-dose administration of infliximab (10 mg/kg, every 8 weeks) or administration with shorter intervals (6 mg/kg, every 4 weeks) are available in case of loss of effect. Torii et al. 9 reported that in their trial with high-dose infliximab no marked differences were noted in the trend of adverse effects from the previously reported safety profile. Adalimumab was found to be superior to placebo and/or methotrexate in four trials. [10] [11] [12] [13] Those data indicate that adalimumab is generally well tolerated for psoriatic patients. 8 In Japan, the dose of adalimumab can be increased from 40 to 80 mg if its effectiveness is not enough. Asahina et al.
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reported no significant increase of severe adverse effects in patients receiving 80 mg every other week of adalimumab, compared with control group or patients receiving 40 mg.
Tuberculosis
Tumor necrosis factor-a plays an important role in immune control of Mycobacterium tuberculosis (TB) infection. [14] [15] [16] It had been reported mainly in rheumatoid arthritis and Crohn's disease (CD) that TNF-a inhibitors increase the incidence rate of active TB. 17, 18 At present, in order to prevent developing active TB and reactivation of latent TB infection (LTBI), tuberculosis screening such as the tuberculin skin test, interferon (IFN)-c-releasing assay, asking about exposure and travel history, chest X ray and chest computed tomography (CT) is recommended prior to initiation of biologic therapy, and during administration of biologics, monitoring tuberculosis regularly is also recommended. 19 Patients with positive screening results and without active disease are to be treated with a full course of chemoprophylaxis. 20 In Japan, patients with positive tuberculin skin test or IFN-c releasing assay are recommended to take 300 mg/day of isoniazid for 6-9 months before initiation of any biologics. In spite of receiving such prophylaxis, some cases in which tuberculosis occurred during biologic therapy have been reported. Therefore, regular examination for tuberculosis is strongly recommended. A meta-analysis of four clinical trials of ustekinumab revealed that the risk of TB with ustekinumab is lower than that observed with anti-TNF-a-therapy. 21 
Paradoxical reaction in TNF-a inhibitors
Although TNF-a inhibitors are effective for psoriasis, psoriatic skin lesions have been reported as one of those adverse effects, which are called a "paradoxical reaction". This is well reviewed in rheumatic patients who were treated with TNF-a inhibitors. 26 Plasmacytoid dendritic cells (pDC) and their production of IFN-a are thought to play a key role in causing psoriatic skin lesions. [27] [28] [29] [30] [31] [32] [33] TNF-a normally inhibits pDC maturation and their IFN-a production. 34 Inhibiting TNF-a allows pDC to produce IFN-a in an unlimited and unregulated way, which causes psoriatic skin lesions. Anti-IFN-a antibody was not effective for plaque psoriasis, 35 suggesting that IFN-a may be important at the initiation of psoriatic skin lesions but that it is considered not to be mainly involved in maintaining psoriatic skin lesions. Skin lesions of paradoxical reaction typically do not require therapy cessation unless they are severe and intolerable lesions or patients prefer discontinuation of TNF-a inhibitors. 26 Takahashi et al. 36 reported a case of a psoriatic patient in whom adalimumab treatment possibly induced new-onset arthritis, successfully treated with ustekinumab. This case could be a paradoxical reaction of adalimumab, although the mechanism is unknown.
Lupus
Bardazzi et al. 37 reported that 37% of 128 psoriatic patients treated with TNF-a inhibitors developed autoantibodies, mostly induced by infliximab (48%). One patient developed drug-induced lupus erythematosus. Vaz et al. 38 reported in a multicenter study that infliximab for various diseases induced a significant increase in the number of patients with antinuclear antibody and anti-dsDNA. Momen et al. 39 recently reviewed 80 patients who developed TNF-a inhibitor-induced lupus. All cases were resolved. The condition of 15 patients was resolved with only withdrawal of the TNF-a inhibitor. Additional immunosuppression in addition to withdrawal of the TNF-a inhibitor was required in the remaining cases. They demonstrated a good prognosis, although treatment should be tailored to each individual case.
Infusion reaction by infliximab
Infliximab is the only biologic administrated i.v. out of the six agents. Infusion reaction occurred in 3-22% of psoriatic patients receiving infliximab. 40 Immediate-type infusion reaction is defined as a reaction that develops during the course of infusion or within 1-2 h of its completion, such as fever, pruritus, flushing, dyspnea, chest discomfort, hypertension, myalgia, nausea, urticaria, headache, rash and dizziness. Although it is rare, severe and life-threatening adverse effects including bronchospasm, angioedema, hypotension and systemic anaphylactic reaction can happen. 41 Physicians in other therapeutic areas have developed strategies for the management of acute infusion reactions. 5, 40, 41 Menter et al. 5 reported that while a majority of anti-infliximab antibody-positive patients did not experience any infusion reaction, antibodypositive patients showed a greater risk of experiencing an infusion reaction than antibody-negative patients. Kim et al.
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found a significantly higher withdrawal rate (8.33%) among the patients receiving infliximab because of infusion reactions than among those receiving etanercept, adalimumab or ustekinumab.
IL-12/23p40 antibody: ustekinumab
Ustekinumab demonstrated superior effectiveness of treatment of psoriasis compared with placebo in five trials.
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The risk of adverse events did no differ significantly between ustekinumab and placebo or between ustekinumab or etanercept. 8 In Japan, the dose of ustekinumab can be increased 63 One of the common adverse effects of interest in IL-17 inhibitors is mucocutaneous candidiasis, yet these infections usually do not lead to interruption of IL-17 inhibitors.
Other adverse effects of interest -although rare -are neutropenia and inflammatory bowel disease. [59] [60] [61] [62] 64, 65 Moreover, the association of brodalumab with depression and suicide has been argued.
Candidiasis
Interleukin-17 plays an important role in innate and adaptive responses against infections, especially those due to Candida species, as evidenced by findings in patients with genetic defects impairing IL-17-related immune responses. 66 In a murine model of oropharyngeal candidiasis, it has been shown that the T-helper (Th)17 lineage confers the dominant response to oral candidiasis. 67 In clinical trials of secukinumab, the overall frequency of Candida infections was low in patients treated with secukinumab, but higher than in placebo and etanercept groups. It displayed dose dependency. 64 In a trial of ixekizumab, Candida infections occurred more frequently in the active treatment groups, exhibiting dose dependence. 59 Brodalumab also showed a high rate of Candida infections compared with ustekinumab and placebo groups. 62 Recently, Saunte et al. 68 systematically reviewed Candida infections in psoriatic patients receiving IL-17 inhibitors. The frequencies of Candida infections were 1.7% in patients treated with secukinumab, 3.3% with ixekizumab, 4.0% with brodalumab, 2.3% with ustekinumab, 0.8% with etanercept and 0.3% in those assigned a placebo. Although the incidence of Candida infection was increased by only a small degree during anti-IL-17 and anti-IL-12/23 therapies, patients should be appropriately monitored and treated as necessary. Almost all Candida infections occurring during anti-IL-17 therapy are mucocutaneous and mild or moderate in severity, which does not usually interrupt administration of IL-17 inhibitors as long as patients are monitored and treated properly.
Neutropenia
The incidence of neutropenia in patients treated with secukinumab, ixekizumab or brodalumab was low, but higher than in those assigned a placebo. Most of those cases were grade 1 or 2, were not associated with infection and resolved spontaneously. In trials with secukinumab, neutropenia of grade 2 or more was more frequently reported in the etanercept group than in secukinumab groups (7.2/100 subject-years compared with 3.8-4.1/100 subject-years), and no dose effect was observed with secukinumab treatment. 64 The incidence of neutropenia of grade 2 or more in patients receiving ixekizumab versus placebo was 2.9% versus 0.4% over 60 weeks. 59 The exposure-adjusted event rates of neutropenia per 100 patientyears of exposure to brodalumab through week 52 were 0.2 in the AMAGINE-2 study and 1.5 in the AMAGINE-3 study; the corresponding rates with ustekinumab were 0.8 in the AMA-GINE-2 study and 0.8 in the AMAGINE-3 study. 62 Although these evidences indicate that neutropenia during anti-IL-17 therapy is rare and -if it happens -mostly mild, it is recommended to monitor the occurrence of neutropenia periodically.
Inflammatory bowel disease
In some papers dealing with animal models of colitis, IL-17 deficiency indicated reduced colitis so that IL-17 inhibitors were expected to be effective for inflammatory bowel disease in humans, too. 69, 70 Unexpectedly, randomized controlled trials for CD with secukinumab and brodalumab resulted in a disproportionate number of cases of worsening and no evidence of efficacy. 65, 71 In addition, exacerbations of inflammatory disease have been reported in psoriatic patients receiving IL-17 inhibitors, although it is already known that prevalence rates of CD and ulcerative colitis (UC) are higher in psoriatic patients than healthy individuals and that psoriasis is more strongly associated with CD than UC. 72 In trials with secukinumab, three cases of CD and four cases of UC were reported out of 3430 subjects over 52 weeks. 64 In those with ixekizumab, four cases of CD and seven cases of UC were reported out of 3736 over 60 weeks. 59 In those with brodalumab, one case of UC was reported out of 1567 over 52 weeks. 62 IL-17 inhibitors are related to exacerbation of inflammatory bowel disease. In treating patients diagnosed with CD or UC, or who have a personal history indicative of inflammatory bowel disease, biologics other than IL-17 inhibitors are to be considered.
Depression and risk of suicide in brodalumab
In the phase 3 studies of brodalumab, three participants attempted suicide with one completion. 62 On the other hand, no other IL-17 inhibitors were associated with depression or suicide in other trials. Since then, the association of brodalumab with suicide has been a concern and argued. It has been reported that psoriasis itself burdens patients psychologically, as evidenced by several papers. 73 any psychological disorder at the time of enrollment or before. Additionally, at the period of the trial, participants in the study were overwhelmingly middle-aged white men, 73% of subjects were male and 91% white with a mean age of 46 years old, a demographic at particular risk of suicide. This risk was likely exacerbated by the socioeconomic disadvantage prevalent in this patient population. 76 Moreover, post-marketing investigation which did not exclude patients who had a present or past medical history of mental disorder demonstrated that suicide ideation, attempted suicide and its completion occurred in patients receiving adalimumab, etanercept or infliximab. 77 Papp et al. 61 reported that brodalumab improved depression and anxiety scores over 12 weeks. Although concerns have been raised regarding the potential link between brodalumab in psoriatic patients and suicide, current published work provides no evidence to support this association. 77 However, brodalumab was approved by the US Food and Drug Administration in February 2017, which has warned of the increased risk of suicidal ideation and behavior.
SAFETY CONCERNS COMMON IN BIOLOGICS Serious infection
Two studies highlighted increased risk of infection as the most significant concern in the long-term use of infliximab. 5, 6 Kimball et al. 78 also reported a cohort study revealing that the rate of hospitalized infectious events for infliximab was higher than other treatment groups including non-biologics, etanercept, adalimumab and phototherapy (incidence rates per 10 000 person-years of exposure and 95% CI were 521 and 278-765 for infliximab, 332 and 256-408 for non-biologics, 288 and 206-370 for etanercept, 325 and 196-455 for adalimumab, and 322 and 219-424 for phototherapy, respectively). Kalb et al. 79 reported that in their cohort study enrolling 11 466 psoriatic patients the cumulative incidence rates of serious infection were 0.83, 1.47, 1.97 and 2.49 per 100 patient-years in the ustekinumab, etanercept, adalimumab and infliximab cohorts, respectively, and 1.05 per 100 patient-years in the non-methotrexate/non-biologics cohort. The most commonly reported types of serious infections were pneumonia and cellulitis. Increasing age, diabetes mellitus, smoking, significant infection history, infliximab exposure and adalimumab exposure were each associated with an increased risk of serious infection.
Hepatitis B and C virus reactivation
Snast et al. 80 published a systematic review of the published work including 49 studies about the risk of hepatitis B and C virus (HBV/HCV) reactivation in psoriatic patients receiving biologics. In 40 patients with chronic HBV infection, viral reactivation was documented in eight (20%) patients and concurrent hepatitis in one patient, for a calculated yearly reactivation rate of 13.92%. An adjusted yearly reactivation rate of patients with chronic HBV infection who received antiviral prophylaxis was 7.74% (3/26), whereas the rate of patients who did not receive antiviral prophylaxis was 26.31% (5/14) . ), only two patients had evidence of viral reactivation, for a yearly reactivation rate of 0.32%. None of the patients had hepatitis. As for HCV infection, in 97 patients with serology suggestive of HCV infection, evidence of viral reactivation was found in three patients (3.09%), for a yearly reactivation rate of 2.42%.
Those results indicate that low-risk patients without hepatitis who are seropositive for HBcAb have minimal risk, but those with HBsAb and/or HBcAb positive are recommended to be monitored periodically during biologic therapy. A recent systematic review reported that a reactivation rate in 712 rheumatic patients with resolved HBV infection who were treated with biologics was 1.7%. 81 The lower risk of HBV reactivation in psoriatic patients may reflect the less frequent use of concomitant immunosuppressants than in rheumatic patients. 82 Patients with chronic HBV infection, characterized by antigen positivity regardless of the status of other serological markers, are at greatest risk for HBV reactivation. 80, 83 In immunosuppressed patients with chronic HBV infection, oral anti-HBV agents have proven to be effective in reducing acute exacerbation and preventing fatal complications. 84, 85 Therefore, all patients with chronic hepatitis B should be treated with antiviral agents before initiation of biologics. Chiu et al. 86 reported a safety profile of reactivation of hepatitis B in patients treated with ustekinumab. Among 11 patients for HBsAg, four patients presented with an increase in their HBV viral loads during ustekinumab treatment, and out of the four patients, two patients fulfilled the criteria for HBV reactivation. The difference of risks among biologics is yet to be elucidated. Therefore, as of now, in psoriatic patients positive for HBsAg, and/or HBsAb, and/or HBcAb, HBV viral load (HBV DNA) should be examined regularly during any type of biologic therapy. For psoriatic patients with HBV infection, antiviral prophylaxis is recommended to minimize the risk of viral reactivation. Regarding HCV infection, the systemic review above suggested that biologics pose no risk of HCV reactivation, considering that 3-10% of patients with HCV infection demonstrated spontaneous fluctuations in viral load of more than 1 log HCV RNA. Nevertheless, since hepatocellular carcinoma and viral reactivation are part of the natural history of HCV, patients should be examined regularly. The limitation of previous papers is that most of patients were treated with TNF-a inhibitors.
Interstitial pneumonia
Increase of serum KL-6 level in psoriatic patients receiving TNF-a inhibitors has been reported recently, [87] [88] [89] [90] although it was already reported in many papers regarding rheumatic patients. 91, 92 In addition, several cases with interstitial pneumonia as an adverse effect of TNF-a inhibitors have been reported in psoriasis 93 as well as rheumatoid arthritis. [94] [95] [96] [97] [98] [99] Although it is still controversial whether TNF-a inhibitors increase a risk of interstitial pneumonia in psoriatic patients receiving biologics, especially TNF-a inhibitors, as of now, psoriatic patients receiving biologics who present elevated serum KL-6 levels are recommended to be examined as to whether they have interstitial pneumonia, Pneumocystis pneumonia, or malignancy by chest X ray or CT following recommendations in the rheumatic field, 91,92 because drug-induced interstitial lung disease had a poor prognosis. 94 A patient receiving ustekinumab who developed interstitial pneumonia was reported. 100 To clarify the association of other biologics such as ustekinumab and IL-17 inhibitors with development of interstitial pneumonia, further accumulations will be needed.
Immunogenicity
Biologics are dramatically effective for psoriasis; however, a substantial portion of patients fail to respond or lose response over time. The presence of anti-drug antibodies (ADA) has been identified as one of the important contributors to failure of treatment and increased risk of adverse events. [101] [102] [103] [104] [105] Formation of immune complex between ADA and biologics is a potential risk of increasing clearance and reducing serum biologic levels, and is thought to have a neutralizing effect on product target binding. The percentages of patients with ADA receiving biologics for psoriasis is as follows: 5.4-43.6% for infliximab, 6.6-44.8% for adalimumab, 3.8-5.5% for ustekinumab, 0.3% for secukinumab, 9.0% for ixekizumab and 1.8-2.3% for brodalumab. 55, 59, 62, 106 Secukinumab has almost no immunogenicity, which may be reason for high effectiveness after secukinumab reinitiation in patients who have interrupted secukinumab once. 107 On the other hand, the percentage of patients with anti-infliximab antibody or anti-adalimumab antibody is higher than that of patients with other biologics, which may account for higher drug survival of ustekinumab than infliximab and adalimumab. 108 At present, data of sustainability, drug survival and withdrawal rate of IL-17 inhibitors are limited, and expected to be accumulated in the near future. Biologic immunogenicity could be affected by structural properties such as difference of chimeric, humanized or human antibody, [109] [110] [111] and effect of glycosylation, 112 contaminants, route of application, 113 dose, administration schedule, 114 formulation and patient characteristics. 115, 116 Maintaining trough concentration high enough may help avoiding unwanted immune response against biologics.
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Malignancy
Kimball et al. 78 conducted a retrospective cohort study including 40 788 people. The results were that incidence rates (95% CI) for all malignancies except non-melanoma skin cancer (NMSC) were 129 (127-130) and 142 (135-149) for general population and psoriasis cohorts, 10.9 (10.5-11.3) and 12.9 (10.9-14.8) for lymphoma, and 145 (144-147) and 180 (173-188) for NMSC, respectively. Rates for all malignancies excluding NMSC were similar among treatments of non-biologics, etanercept, adalimumab, infliximab or phototherapy, but variable for lymphoma and NMSC. They concluded that malignancy rates were higher in psoriatic patients than the adult general population, but these treatments did not appear to increase malignancy risk.
CONCLUSION
The advent of biologics dramatically brought a paradigm shift in treatment of psoriasis. At first, adverse events of biologics were of great concern. However, now we know that biologics are administrated quite safely under appropriate monitoring. In terms of safety profile, generally the incidence of severe adverse effects in psoriatic patients receiving anti-IL-12/23 antibody or IL-17 inhibitors is lower than that of TNF-a inhibitors, although that of TNF-a inhibitors is still very low. Regarding IL-17 inhibitors, they came on the market recently. More data about safety profile are expected to be accumulated. New biologics, IL-23p19 inhibitors such as risankizumab, guselkumab and tildrakizumab are due to become available in a couple of years. There is more expectation for doctors to know enough about safety as well as efficacy to treat psoriatic patients with biologics.
